However if Celgene is able to gain approval for use in psoriasis as well, this will boost its revenues. The drug was filed in Europe in January this year, with a European approval launch ...

Celgene's drug Otezla (apremilast) is an oral, selective inhibitor of phosphodiesterase 4 (PDE4) and gained its first approval in March this year for the treatment of psoriatic arthritis.

Celgene's apremilast ... 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

Celgene (Warren, NJ), a developer of chirally pure drugs, agreed on June 30 to purchase gene-regulation firm Signal Pharmaceuticals (San Diego, CA) for $200 million in an all-stock deal.

He has also been a consultant to: Abbvie, Celgene, Amgen ... further studies to look at IL-17 blockade in psoriasis. Currently, three different drugs that attempt to modify the interaction ...